Alice Y. Cheng, Asoociate Professor (she/her/hers)

Dr. Cheng is an Endocrinologist at Trillium Health Partners and Unity Health Toronto and an Associat
University of Toronto
University of Toronto
Toronto, Ontario, Canada

Dr. Cheng is an Endocrinologist at Trillium Health Partners and Unity Health Toronto and an Associate Professor at the University of Toronto. She has been involved with the development of the Diabetes Canada clinical practice guidelines since 2003 and served as Chair for the 2013 version. She is immediate Past-Chair of the Professional Section of Diabetes Canada and is serving as Chair of the Scientific Planning Committee for the 2023 and 2024 American Diabetes Association annual scientific meetings. In addition, she is an Associate Editor for Diabetes Care and co-host of the podcast series “Diabetes Care On Air”. In recognition of her contribution to the diabetes community, she has received the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada. She is also the creator of The Med Ed Pledge – an initiative to increase Diversity & Inclusion in continuing medical education (www.theMedEdPledge.com) along with CMEX – a searchable database of health care professionals interested in contributing to medical education.

Presentation(s):

• CC10 - Vascular Protection in Patients Living with Diabetes: A Global Approach

  Thursday, November 21, 2024
  16:05 - 16:25 AT Time

  Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); Astra Zeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly & Company: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline: Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); Novo Nordisk A/S: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing)

• CC05 - Minimizing Risk of Hypoglycemia with Daily Glucose Management in Diverse Populations

  Thursday, November 21, 2024
  17:35 - 17:55 AT Time

  Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); Astra Zeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly & Company: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline: Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); Novo Nordisk A/S: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing)

• DC2427 - The Big Debate: To stay on medications or not to stay on medications when people are at glycemic target

  Friday, November 22, 2024
  16:00 - 17:15 AT Time

  Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); Astra Zeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly & Company: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline: Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); Novo Nordisk A/S: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing)

• DC2428 - All Things New: Hot topics from 2024

  Saturday, November 23, 2024
  08:15 - 09:30 AT Time

  Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); Astra Zeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly & Company: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline: Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); Novo Nordisk A/S: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing)